Multiple research teams are now testing vaccines designed to train the immune system against the parts of influenza that barely change from year to year, a strategy that could eventually replace the annual flu shot. A chimeric hemagglutinin approach has already shown it can redirect human immune responses toward the conserved stalk of the virus and its internal nucleoprotein, while separate programs target other slow-mutating proteins such as M2. The work arrives as the World Health Organization recently recommended changing all three viral strains in seasonal flu shots for the upcoming fall season, a reminder of how quickly the virus outpaces conventional vaccines.
Why the Virus Keeps Winning the Annual Race
Seasonal flu vaccines are reformulated every year because the hemagglutinin protein on the virus surface, the main target of traditional shots, mutates rapidly in its bulbous “head” domain. That head region dominates the immune response, so antibodies generated by one season’s vaccine often fail against the next season’s drifted strain. Interim analyses from the 2025-26 flu season indicate that current flu vaccines provide moderate protection against severe disease, a performance ceiling that has persisted for decades.
The WHO’s decision to update all three viral components, including the H1N1 influenza A strain, for fall shots highlights the treadmill effect: public health authorities must predict which variants will circulate months before flu season begins, and mismatches erode effectiveness. A universal vaccine would sidestep this guessing game by aiming at regions of the virus that remain stable across subtypes and seasons. The National Institute of Allergy and Infectious Diseases has defined a universal influenza vaccine by its required breadth and durability, outlining conserved targets such as the HA stalk, neuraminidase, and T-cell antigens as the most promising avenues.
Chimeric Proteins Trick the Immune System
The core technical challenge is that the conserved regions of influenza are normally immunosubdominant, meaning the immune system overlooks them in favor of the flashier, fast-changing head. Researchers have responded with chimeric hemagglutinin constructs that pair an exotic head from a rare avian subtype with the conserved stalk from a human-circulating strain. Because the immune system has no prior memory of the unfamiliar head, it is forced to generate antibodies against the stalk instead. A Phase 1 randomized, placebo-controlled trial tested this idea using a live-attenuated prime followed by an inactivated boost, comparing adjuvanted and unadjuvanted formulations. The interim results, published in The Lancet Infectious Diseases, confirmed that the chimeric HA vaccines induced measurable antibodies targeting the conserved stalk with a safety profile typical for early-stage trials.
A follow-up analysis published in EBioMedicine extended those findings by showing the chimeric HA strategy also boosted human cellular immune responses directed at the viral nucleoprotein, an internal protein that changes slowly across influenza subtypes. That dual effect matters because antibodies alone may not be enough; T cells that recognize conserved internal proteins can kill infected cells even when the surface proteins have shifted. The ability of a single vaccine platform to engage both arms of immunity, antibodies against the stalk and T cells against nucleoprotein, represents a meaningful advance over earlier designs that focused on one target at a time.
Beyond the Stalk: Other Conserved Targets
The HA stalk gets the most attention, but it is not the only conserved region scientists are exploiting. Research presented at the FDA Science Forum described a vaccine based on the conserved antigens nucleoprotein (NP) and matrix protein 2 (M2), both slow-changing internal or structural proteins. In animal models, this approach provided protection against diverse influenza A subtypes and influenza B challenge, with immunity lasting out to one year post-vaccination. A separate nanoparticle-based vaccine elicited broadly neutralizing antibodies targeting conserved regions not just in the stalk but also in the HA head itself, including the receptor-binding site and the vestigial esterase subdomain, according to data from a Phase 1 human study.
Yet another approach, described in a Science paper, involves covalently linking hemagglutinins from different subtypes to reduce the immune system’s natural bias toward whichever strain it encountered first in childhood. This antigen-coupling method broadened both antibody and T-cell responses and improved recognition of avian influenza HA in model systems, according to NIH researchers who used identical twin cohorts, infant cohorts, and tonsil organoid experiments to map how prior exposure shapes the response. That line of work directly addresses one of the hardest problems in flu vaccinology: immune imprinting, where the body’s first encounter with influenza biases all future responses toward that original strain.
New Trials Signal Growing Confidence
The pipeline of universal flu vaccine candidates has expanded noticeably. South San Francisco-based Centivax, Inc., a clinical-stage biotechnology company, initiated a Phase 1 first-in-human clinical trial of its own universal flu vaccine candidate designed to induce antibodies against conserved epitopes across group 1 and group 2 influenza A viruses. Early-stage work from the company, described in a recent preclinical report, showed that a structure-guided immunogen could elicit broadly neutralizing responses in animals and protect against lethal challenge with mismatched strains. Those data helped justify moving into human testing, where investigators will now examine safety, dose levels, and the breadth of antibody responses across diverse influenza subtypes.
Other teams are also advancing candidates into the clinic. In one Phase 1 trial of a multivalent nanoparticle vaccine, volunteers developed cross-reactive antibodies and memory B cells that recognized a wide range of H1 and H3 viruses, with responses persisting for months after vaccination. A related effort using rationally designed HA molecules, sometimes described as “designer proteins,” aims to present conserved regions in highly ordered arrays that focus B cells on the right targets. Together, these programs suggest that the field is moving beyond proof-of-concept into a phase where multiple platforms (viral vectors, protein nanoparticles, and mRNA) are being compared head-to-head for their ability to generate broad, durable protection.
What Universal Vaccines Could Change
If even one of these approaches succeeds, the impact on public health could be substantial. Modeling studies based on historical surveillance data suggest that a vaccine providing multi-year protection against a broad panel of influenza A and B viruses could sharply reduce hospitalizations and deaths, especially in older adults and people with chronic conditions. A recent review of the universal vaccine landscape noted that combining B-cell and T-cell targets, such as HA stalk epitopes with internal proteins like NP and M1, may be the most promising way to achieve this goal, because it layers neutralizing antibodies on top of cross-reactive cellular immunity. Investigators writing in an open-access overview of next-generation candidates argued that such multi-component designs are also more resilient to viral evolution, since it would take simultaneous changes at several sites to erode protection.
For now, however, universal influenza vaccines remain an aspiration rather than a replacement for the yearly shot. The immune system’s tendency to focus on variable regions, the complexity of immune imprinting, and the need to demonstrate efficacy against naturally circulating strains all pose challenges that early-stage trials cannot fully answer. Large, multi-season studies will be required to show that these new candidates truly outperform updated conventional vaccines in real-world settings. Still, the convergence of chimeric HA constructs, conserved internal antigens, and structure-based design has moved the field further along than at any point in the past, raising the possibility that the annual scramble to keep up with the virus may eventually give way to longer-lasting, broadly protective immunization strategies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
